Ganga Pharmaceuticals Limited (BOM:539680)
India · Delayed Price · Currency is INR 12.50
+0.50 (4.17%)
At close: Sep 8, 2026
Ganga Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 28.78 | 28.28 | 26.37 | 27.36 | 25.86 | 24.89 |
Other Revenue | -0.57 | - | - | -0 | - | - |
| 28.21 | 28.28 | 26.37 | 27.36 | 25.86 | 24.89 | |
Revenue Growth | 4.76% | 7.22% | -3.60% | 5.78% | 3.91% | 4.83% |
Cost of Revenue | 14.11 | 13.11 | 12.19 | 12.51 | 12.49 | 12.92 |
Gross Profit | 14.1 | 15.17 | 14.18 | 14.85 | 13.38 | 11.97 |
Selling, General & Admin | 5.68 | 6.13 | 5.92 | 5.91 | 5.21 | 5.12 |
Other Operating Expenses | 8.65 | 8.65 | 9.42 | 8.37 | 8.13 | 6.43 |
Operating Expenses | 14.91 | 15.34 | 15.81 | 14.77 | 13.89 | 12.1 |
Operating Income | -0.82 | -0.17 | -1.63 | 0.08 | -0.51 | -0.13 |
Interest Expense | -1.12 | -1.23 | -1.69 | -1.81 | -1.87 | -1.9 |
Interest & Investment Income | 2.79 | 2.79 | 2.48 | 2.39 | 2.98 | 2.59 |
Other Non Operating Income (Expenses) | 0.05 | -0.1 | -0.1 | -0.04 | -0.07 | -0.04 |
EBT Excluding Unusual Items | 0.91 | 1.29 | -0.93 | 0.63 | 0.53 | 0.51 |
Gain (Loss) on Sale of Assets | - | - | 1.88 | - | - | - |
Pretax Income | 0.91 | 1.29 | 0.95 | 0.63 | 0.53 | 0.51 |
Income Tax Expense | 0.26 | 0.28 | 0.16 | 0.17 | 0.14 | 0.13 |
Net Income | 0.65 | 1.02 | 0.79 | 0.47 | 0.39 | 0.38 |
Net Income to Common | 0.65 | 1.02 | 0.79 | 0.47 | 0.39 | 0.38 |
Net Income Growth | -18.34% | 28.48% | 69.46% | 18.60% | 3.74% | 86.16% |
Shares Outstanding (Basic) | 2 | 6 | 5 | 5 | 4 | 4 |
Shares Outstanding (Diluted) | 2 | 6 | 7 | 7 | 4 | 4 |
Shares Change | -70.74% | -10.59% | - | 62.79% | - | - |
EPS (Basic) | 0.30 | 0.17 | 0.16 | 0.10 | 0.10 | 0.09 |
EPS (Diluted) | 0.30 | 0.17 | 0.12 | 0.07 | 0.10 | 0.09 |
EPS Growth | 173.68% | 41.67% | 71.43% | -27.67% | 7.53% | 80.00% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -5.57 | -13.48 | -6.76 | -12.86 | -0.55 | -2.25 |
Free Cash Flow Per Share | -2.61 | -2.28 | -1.02 | -1.95 | -0.14 | -0.56 |
Gross Margin | 49.97% | 53.65% | 53.77% | 54.29% | 51.73% | 48.10% |
Operating Margin | -2.89% | -0.59% | -6.17% | 0.31% | -1.99% | -0.51% |
Profit Margin | 2.31% | 3.59% | 3.00% | 1.70% | 1.52% | 1.52% |
Free Cash Flow Margin | -19.74% | -47.65% | -25.63% | -47.02% | -2.11% | -9.06% |
EBITDA | -0.23 | 0.39 | -1.16 | 0.58 | 0.05 | 0.42 |
EBITDA Margin | -0.81% | 1.38% | -4.41% | 2.11% | 0.18% | 1.69% |
D&A For EBITDA | 0.59 | 0.56 | 0.47 | 0.49 | 0.56 | 0.55 |
EBIT | -0.82 | -0.17 | -1.63 | 0.08 | -0.51 | -0.13 |
EBIT Margin | -2.89% | -0.59% | -6.17% | 0.31% | -1.99% | -0.51% |
Effective Tax Rate | 28.23% | 21.50% | 16.58% | 26.33% | 26.01% | 26.00% |
Revenue as Reported | 31.91 | 31.07 | 30.73 | 29.75 | 28.85 | 27.48 |
Advertising Expenses | - | 0.25 | 0.15 | 0.11 | 0.1 | 0.13 |